China Pharma Holdings, Inc. — Q2 2012 Form 10-Q
Reporting period: Three and six months ended June 30, 2012; interim financial statements are unaudited. The company manufactures and sells generic and branded pharmaceuticals in China, primarily through distributors serving hospitals and retailers.
Financial performance
| Metric (USD unless stated) | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $14.60 million | $19.60 million | $30.69 million | $37.72 million |
| Gross profit / margin | $4.14 million / 28.3% | $7.28 million / 37.2% | $9.44 million / 30.8% | $14.15 million / 37.5% |
| Operating income | $2.21 million | $5.76 million | $5.62 million | $11.10 million |
| Net income | $1.76 million | $5.07 million | $4.57 million | $10.17 million |
| Basic and diluted EPS | $0.04 | $0.12 | $0.10 | $0.23 |
| Operating cash flow | Not separately presented by quarter | $1.89 million | $3.61 million |
- Q2 revenue declined 25.5% year over year; net income fell 65%. For the first half, revenue declined 18.7% and net income fell 55.1%.
- Gross-margin pressure was broad: Q2 margins weakened particularly in CNS/cardiovascular (29.8% versus 42.9%), digestive (28.3% versus 45.7%), and other products (33.7% versus 42.5%).
- At June 30, cash and cash equivalents were $4.87 million; banker's acceptances were $0.46 million. Current assets were $118.17 million and current liabilities $16.56 million. The balance sheet reports total liabilities of $16.72 million.
- Short-term bank notes payable were $3.96 million, bearing 7.54% interest and secured by certain land-use rights and buildings. No additional amounts were available under the credit line. A director advanced $293,004 during the half at 1% interest, due December 31, 2012.
- Cash increased $0.82 million during the half. Investing activities used $1.34 million, primarily for drug-formula advances and property and equipment; financing provided $0.29 million.
Changes, outlook, and risks
- Management attributed lower sales partly to reducing credit sales to improve collections and to disruption from changing healthcare-reform policies. Sales declined across all reported product categories.
- Management expects pharmaceutical pricing pressure to continue, with healthcare reform, Essential Drug List pricing, and uneven regional pricing affecting sales and margins. It believes Candesartan and Rosuvastatin could support margins if launched; the filing provides no quantified financial guidance.
- The company reported $71.36 million of net trade receivables, up from $69.70 million at year-end, and a $4.11 million allowance for doubtful accounts. Receivables more than 90 days old were $59.7 million; 29.9% of receivables were aged 360–720 days. Management said it had not historically written off customer receivables, but increased aging drove $553,237 of first-half bad-debt expense.
- Inventory rose to $36.40 million from $30.38 million. Operating cash flow was lower year over year, with receivables and inventory increases consuming cash.
- Management expects continued pricing pressure and is upgrading its facility to stricter Chinese GMP standards, with a compliance grace period of up to three to five years depending on product risk. Pipeline products remain subject to clinical trials and/or SFDA approval: the antibiotic is in Phase II, the heart-disease drug in Phase III, and Candesartan and Rosuvastatin await production approval. Approval and launch timing are uncertain.
- Cash held in the PRC may be restricted from transfer: management says $5.28 million of cash and banker's acceptances is indefinitely reinvested in the subsidiary, and PRC foreign-exchange conversion and remittances require government approval. The balance-sheet amounts sum to approximately $5.33 million, so the MD&A figure should be reconciled.
- Other notable comparison items: the prior-year half included a $0.93 million derivative gain and $0.15 million government subsidy; neither recurred in 2012. The CFO's employment ended in April; the CEO became interim CFO. A 100,000-share grant in connection with cancellation of vested options resulted in $55,775 of compensation expense.
- The company reported no material off-balance-sheet arrangements or commitments outside ordinary-course expenditures. Management concluded disclosure controls were effective and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Whether the aged receivables are collectible and whether the allowance adequately reflects collection risk.
- Reconciliation of the reported $5.28 million of cash and banker's acceptances with the balance-sheet total of approximately $5.33 million, and how much cash is practically available to the parent.
- Progress and costs of the GMP upgrade, and actual SFDA approval and launch prospects for pipeline products.
- Whether sales, gross margins, and operating cash flow stabilize amid healthcare-reform pricing pressure and elevated inventory.
- Terms and classification of related-party amounts, including the director advance, and the company's short-term borrowing and repayment needs.